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Abstract  
 
Chronic respiratory disease can affect growth or nutrition, which can influence lung function. We 
investigated height, body mass index (BMI), and lung function in patients with primary ciliary 
dyskinesia (PCD).  
In this large study based on the international PCD (iPCD) Cohort, we calculated z-scores for 
height and BMI using World Health Organization (WHO) and national growth references, and 
assessed associations with age, sex, country, diagnostic certainty, age at diagnosis, organ 
laterality, and lung function in multilevel regression models accounting for repeated 
measurements. 
We analysed 6402 measurements from 1609 from iPCD Cohort patients. Height was reduced 
compared to WHO (z-score -0.12, 95% CI -0.17 to -0.06) and national references (-0.27, -0.33 
to -0.21) in male and female patients in all age groups, with variation between countries. Height 
and BMI were higher in patients diagnosed earlier in life (p=0.026 and <0.001, respectively) and 
closely associated with FEV1 and FVC z-scores (p<0.001).  
Our study indicates that growth and nutrition are impaired in PCD patients from early life and 
are strongly associated with lung function. If supported by longitudinal studies, this suggests 
that early diagnosis with multidisciplinary management and nutritional advice could improve 
growth and delay disease progression and lung function impairment in PCD. 
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Introduction 
Chronic respiratory disease may delay growth and weight gain in children, and lead to reduced 
height and body mass index (BMI) in adults. Both a disease and its treatments may cause this 
delay [1,2]; children with asthma grow more slowly because of higher resting energy 
expenditure [3] and delayed pubertal onset [4], or because of corticosteroid medication [5]. 
Growth and nutrition in childhood are also associated with lung function later in life in patients 
with cystic fibrosis (CF) and bronchopulmonary dysplasia [6,7]. Monitoring of BMI and height is 
thus part of state-of-the art care of patients with chronic lung diseases such as chronic 
obstructive pulmonary disease and CF [8,9], just as they are used as indicators of growth and 
nutritional status in healthy individuals [10]. Though growth and nutrition in children with 
common lung diseases like asthma are well studied, we still know little about height and BMI in 
patients with rare pulmonary diseases such as primary ciliary dyskinesia (PCD). 
The genetically heterogeneous disease primary ciliary dyskinesia affects approximately 1 in 
10,000 people; though rare, it is likely underdiagnosed [11]. PCD is characterized by mutations 
that impair the function of motile cilia, thus affecting organs throughout the body— the 
respiratory system in particular [12]. The few studies published so far on growth have been 
contradictory: some suggest impaired growth [13-15], while others do not [16,17]. All were 
small, included mainly children, and came from one or only a few centres. A further limitation of 
existing research originates in the reference values for height and BMI. These vary between 
countries, yet studies have rarely used national reference values [15,17], which are necessary if 
the growth of PCD patients is to be compared with that of their healthy peers. 
We hypothesize that height and BMI of PCD patients are already impaired in early childhood, 
and are associated with lung function as in other severe lung diseases. We obtained height and 
BMI of patients in the international PCD (iPCD) Cohort, which we compared to national and 
international reference values. We investigated determinants of poor growth including sex, age, 
country of residence, and level of diagnostic certainty. We also investigated growth in paediatric 
patients and its dependence on the age when patients were diagnosed with PCD, and whether 
their growth was associated with their lung function.  
 
  
5 
 
Methods 
Study population and study design 
The iPCD Cohort is a large, retrospective international cohort developed during the EU FP7 
(Seventh Framework Programme) project Better Experimental Screening and Treatment for 
Primary Ciliary Dyskinesia (BESTCILIA). It includes demographic data and information on 
diagnostic tests, clinical symptoms, growth, lung function, and treatment. Clinical and diagnostic 
data from over 3000 PCD patients in 18 countries allow researchers to pose questions about 
clinical phenotype, natural history, prognostic factors, and effect of treatments. Details on the 
iPCD Cohort have been described elsewhere [18]. For this study we included all iPCD datasets 
that had been delivered, cleaned, and standardised by the time of analysis (April 2016), and that 
had cross-sectional information on height and weight. Information on ethical approval can be 
found in the online supplementary material. 
 
PCD diagnosis 
PCD diagnostics have evolved quickly [19]. Current recommendations include a combination of 
tests [20], but test availability differs between countries [19]; not all PCD patients have been 
diagnosed in similar ways. We divided patients in the iPCD Cohort, who all had a strong clinical 
suspicion, into three diagnostic subgroups based on the results of the available tests. The first 
subgroup included patients with definite PCD, which was defined, based on recent guidelines of 
the ERS PCD Diagnostics Task Force [20], by hallmark transmission electron microscopy (EM) 
findings and/or identified biallelic PCD genetic mutation. The second subgroup, probable PCD, 
included patients with abnormal high-speed video-microscopy (VM) findings and/or low nasal 
nitric oxide (nNO). The third subgroup included patients with clinical PCD diagnosis. The online 
supplement describes diagnostic details. 
 
Height and BMI 
We checked data quality to identify outliers and implausible values and contacted contributors 
when necessary to resolve any such matters. We calculated age- and sex-adjusted height and 
BMI z-scores based on international reference values from the World Health Organisation 
(WHO) [21], and national reference values (the sources are listed in the online supplement, 
Table S1).  
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Growth references available for height and BMI were intended for persons up to 19 years of age 
(or in some countries up to the age of 20). For patients aged <20 years, we calculated height 
and BMI z-scores based on the exact age-specific references. For patients aged ≥20 years, we 
calculated height z-scores based on the reference values for 19-year-olds; these describe final 
adult height. We also calculated BMI z-scores for adults based on the reference values for 19-
year-olds because no BMI z-score references exist for adults. We defined short stature as a 
height z-score ≤-2, underweight as a BMI z-score ≤-2, and overweight as a BMI z-score ≥2 
according to the definitions used by WHO. 
 
Determinants of height and BMI 
We investigated association of the following factors with height and BMI: sex, age, country of 
residence, level of diagnostic certainty, age at diagnosis, organ laterality, and lung function at 
time of height measurement. Growth might differ in male and female patients with PCD, and 
manifest as slowed growth and/or malnutrition in childhood, and decreased final adult height. 
Differences between countries could reveal ethnic variations or differences in disease 
management. In children diagnosis at younger age might improve growth since it would allow 
earlier introduction of optimal disease management. Patients with situs inversus might have less 
severe disease because they were diagnosed earlier, before symptoms develop. Details 
regarding how we categorised the variables chosen are in the online supplement.  
 
Lung function  
We chose forced expiratory volume in one second (FEV1), and forced vital capacity (FVC) as  
indicators of lung function and used the Global Lung Function Initiative (GLI) reference values to 
calculate age, sex, ethnicity, and height-adjusted z-scores [22]. All lung function measurements 
were checked for quality, and since 2005 they were performed according to the ERS/ATS 
guidelines [23]. Earlier measurements were performed according to national recommendations. 
 
Statistical analysis 
We compared basic characteristics (sex, age, country) of included and excluded (no available 
growth measurements) patients using chi-squared tests. We compared height and BMI z-scores 
of the overall study population to national and WHO reference values using mixed linear 
regression models with a fixed intercept (difference to reference population), and random 
7 
 
intercept to account for repeated measurements of the same patient. To identify determinants of 
height and BMI, we additionally included fixed effects for sex, age group, country, and 
diagnostic certainty in these models. We tested for height and BMI differences between patient 
groups by performing likelihood ratio (LR) tests. We coded categorical predictor variables 
included in regression models using weighted effect coding. Estimated parameters for a given 
category thus represent mean z-score differences from the population mean [24,25]. We 
performed sensitivity analyses in the subgroup of patients with definite PCD diagnosis [20]. To 
test the robustness of our findings, we performed sensitivity analyses including one 
measurement (height and BMI) per patient. 
We then repeated our analyses for height separately for children (age <20) and adults (age ≥20) 
to investigate whether the disease only slowed growth or also influenced final adult height. For 
BMI, we repeated our analysis in children only because BMI z-score references for ≥20-year-
olds do not exist. We included age at diagnosis in the multivariable linear regression models for 
children to test whether age at diagnosis influenced growth and nutrition. 
Finally, we assessed the association between FEV1 and FVC and height and BMI in separate 
multivariable linear regression models in patients with information on lung function. FEV1 and 
FVC were included as a linear term after visually inspecting scatter plots. We used the statistical 
programs STATA 14.1 and R 3.2.3 for all analyses. 
  
Results 
Population characteristics 
Twenty centres had delivered data from 2675 patients at the time of analysis, and 18 of the 
datasets from 16 countries (2131 patients) contained information on growth (Figure S1). The 
information necessary to calculate z-scores (height, weight, date of measurement, sex) was 
available for 1609 patients (6402 measurements). Analyses of organ laterality defects and lung 
function included 1054 and 959 patients, respectively. 
Included patients were slightly older than patients excluded because of insufficient growth data 
(Table S2, p<0.001), and differed in country of residence (p<0.001). Sex was almost evenly 
distributed, and more than half the patients (58%) came from European centres. Table 1 
summarises the characteristics of the study population. Using the recent ERS PCD Diagnostics 
Task Force guidelines [20], 66% of patients were defined as having definite PCD, 16% as 
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having probable PCD, and 18% as having only a clinical diagnosis. Most of the patients were 
diagnosed during childhood (50% at 0-9 years, 28% at 10-19 years).  
 
Height and BMI in PCD patients compared to national and international reference values 
PCD patients were shorter when compared to both national and international references (Table 
2). Lower height was consistent across gender and age groups, and 146 patients (9%) had a 
short stature (Table 3, Figure 1). Results differed between countries, but height was usually 
lower than respective national references (Table 3, Figure 2). Only patients living in Cyprus, 
France, and Switzerland had normal height z-scores. The small difference in height between 
males and females did not quite reach statistical significance (LR p=0.072). We found no height 
difference between levels of diagnostic certainty compared to both national and WHO 
references (LR p=0.897, p=0.531; Tables 3 and S3). Height deficit differed between the age 
groups, with the larger deficit in children (LR p<0.001, Table 3). 
Overall, the average BMI of PCD patients was slightly above normal when compared to national 
and international references (Table 2). In at least one measurement during the study period, 
105 patients (6%) were underweight, while 405 (25%) were overweight. Children ≤9 years had 
lower BMI than normal compared to national references (Table S4, Figure 3). Results for BMI 
differed by age group, with increasing z-scores in older participants (LR p<0.001), and by 
country. In most countries, BMI was higher than national references; in a few it was similar 
(Table S4, Figure 2). Only patients from Cyprus had decreased BMI. BMI was higher in males 
than females (LR p=0.019, Table S4) but did not differ across diagnostic groups (Table S4). 
Results were similar when compared to the WHO references, with slightly higher z-scores in all 
countries except France and the Netherlands (Table S5). 
Organ laterality did not predict height or BMI (Figure S2, LR p>0.698). Sensitivity analyses that 
included only patients with definite PCD diagnosis (1054 patients) and the ones that included 
only one measurement per patient (1601 patients) returned results for height and BMI that were 
similar to the original model (Tables 2 and S6-S9).  
 
Growth in children and association with age at diagnosis 
Analyses of the 1226 paediatric patients confirmed decreased height in children with PCD 
(Tables 2 and S10). The deficit differed between age groups (LR p=0.008, Table S6). Patients 
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diagnosed later, aged ≥15 years, had a larger height deficit (LR p=0.026, Table S10). The final 
height of the 439 adult patients was reduced (Tables 2 and S7) in both sexes and all diagnostic 
groups (Table S11), and results differed by country (LR p<0.001).   
BMI in children was, overall, similar to national references (Tables 2 and 4), but increased with 
age (LR p<0.001): preschoolers (≤4 years) had lower BMI z-scores (Table 4). Age at diagnosis 
was linearly associated with BMI z-score (LR p<0,001); children diagnosed earlier had higher 
BMI at time of measurement than children diagnosed later in life (Table 4). Children diagnosed 
at age ≤4 years had higher BMI z-scores than normal, while those of children diagnosed at age 
≥15 years were lower. 
 
Association with lung function 
In 959 patients with available lung function data (median age 16 years, interquartile range 19), 
we found a positive association between height and BMI, and FEV1and FVC measured at the 
same time (Figure 4). Patients with higher FEV1 z-score were taller (z-score increase per 
additional FEV1 z-score 0.05, p<0.001; 95% CI 0.04 to 0.07) and had a higher BMI z-score (z-
score increase per additional FEV1 z-score 0.17, p<0.001; 95% CI 0.15 to 0.19). Similarly, 
patients with higher FVC z-score had a higher height z-score (z-score increase per additional 
FVC z-score 0.03, p<0.001; 95% CI 0.02 to 0.05) and had a higher BMI z-score (z-score 
increase per additional FEV1 z-score 0.17, p<0.001; 95% CI 0.09 to 0.24). 
 
Discussion 
Summary of results 
The height z-scores of the PCD patients were lower than both international and national growth 
references. All of the multinational age groups, including fully matured adults, were shorter than 
the reference population. BMI was slightly higher in the overall cohort, but was lower than 
normal in young children. These results were consistent across all diagnostic and organ 
laterality subgroups. Diagnosis at later age was associated with lower height and lower BMI in 
children, and lung function (FEV1 and FVC) was positively associated with both height and BMI 
in males and females and all age groups.  
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Strengths 
The iPCD dataset represents most known PCD patients currently being followed in developed 
countries. Our study group is thus an order of magnitude larger than that of any previous study 
that has examined growth and nutrition in patients with PCD and their association with lung 
function. This has for the first time allowed study of differences in height and BMI of PCD 
patients between age groups, countries, and levels of diagnostic certainty. 
PCD diagnosis has changed over time and varies between countries. We therefore 
strengthened our analysis with sensitivity tests that included only patients with a definite PCD 
diagnosis based on the recent diagnostic guidelines from the ERS PCD diagnostics Task Force 
[20]. The results are further strengthened by our use of both international and national reference 
values, rather than having relied solely on WHO Child Growth Standards. Paediatric 
associations often prefer national references, which allow growth comparison of sick children 
with healthy peers from the same country [26].  
 
Limitations 
The iPCD Cohort includes patients primarily from centres that have more advanced diagnostic 
capabilities; patients in some countries are under-represented. Growth patterns may have 
shifted as well in some countries in which national references have not been updated. 
We compensated for the lack of references for adults as other studies have done by calculating 
BMI z-scores for adult patients based on the reference values for 19-year-olds [27]. This is not 
fully satisfactory, though, because as the Swiss Health Survey makes clear BMI increases with 
age [28]. We therefore think our BMI results are valid primarily for children. For adults we would 
need a comparison, currently beyond the scope of this study, of PCD patients with appropriate 
adult control groups. 
Information on ethnicity was not recorded for all patients, so height and BMI z-scores were 
calculated using national references of countries of residence. For patients of unknown 
ethnicity, we calculated FEV1 and FVC z-scores using the other/mixed GLI reference values. 
We assume that this affected our results only marginally, particularly because patients with 
possible South Asian origin who are known to have different lung function reference values 
were less than 5% of our study population.  
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Comparison with other studies 
Results of previous studies of growth and PCD vary considerably (Table S12). In a Belgian 
comparison of 168 PCD patients with national references, the PCD patients were shorter (z-
score −0.53, 95% CI −0.85 to -0.22), but had normal BMI [13]. In six North American centres, 
most of the 118 children fell within normal parameters, but children with CCDC39 and CCDC40 
mutations had lower height, BMI, and FEV1 compared to those with different mutations [16]. A 
comparison of the height and BMI of 158 paediatric patients at three centres in Italy, Denmark, 
and the UK, with UK growth references, concluded that height and BMI were normal [17]. A 
different, Czech comparison of PCD patients to national references found that children aged 7-
13 years were shorter, though BMI in all age groups was normal. Their height z-scores declined 
during childhood until age 9 years, but height difference did not depend on age at diagnosis 
[14]. However, each of these comparisons with respective UK and Czech national references 
was small and lacked power. 
For other respiratory diseases, associations between growth and nutrition, and lung function 
have been studied extensively. Taking the example of bronchopulmonary dysplasia, the 
nutritional status of two-year olds predicted lung function in later childhood [6]. Similarly for CF, 
patients with better growth and nutrition at 3 years also had better lung function when they were 
6 [7]. And in a comparison of PCD and CF patients in Israel, BMI was lower in 34 PCD patients 
than it was in 130 CF patients (with and without pancreatic insufficiency), and BMI and FEV1 
tended towards correlation (r=0.44, p=0.06) [15]. 
 
Interpretation of results  
What does all this mean? It is not possible to derive the direction of the association between 
growth and lung function from cross-sectional data. Yet it certainly is possible, and probable, 
that poorer lung function resulting in increased respiratory effort and higher resting energy 
expenditure can affect growth in PCD patients. Impaired nutrition—caused, for example, by 
reduced appetite due to swallowed sputum or repeated infections—could additionally impair 
lung development [29]. This is supported by evidence from CF, which indicated that nutritional 
support helped reduce mortality [30,31].  
Our data suggest more strongly than any obtained to date that growth in PCD patients starts to 
diverge from normal at an early age. This could imply a genetic cause. Prevalence of PCD is 
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higher in consanguineous populations [32], and inbreeding has been reported to contribute to 
reduced height [33]. Primary (nonmotile) cilia play a role in mechanical signalling in bone cells, 
but a possible role in skeletal growth has not been tested [34]. A recent study has reported mild 
scoliosis in 23% of 198 UK PCD patients, which could have an additional effect that reduces 
height [35]. Height and BMI were lower in children with CCDC39 and CCDC40 mutations [16], 
which cause specific ultrastructural defects (absence of inner dynein arms and microtubular 
disorganisation), and account for up to 12% of PCD cases [36,37]. We had genetic data for only 
a few patients and could not pursue this further. However, based on their low prevalence these 
mutations alone could not explain our findings.  
Chronic and recurrent infections, common in PCD, may negatively influence the periods of rapid 
growth in childhood when nutrients needed for growth might be used for immune defence 
[38,39]. Alternatively, oral or inhaled corticosteroids (ICS) may play a role. An earlier European 
survey of PCD centres reported routine use of ICS in 15% of centres, particularly in Northern 
Europe [40]. PCD patients might also have been misclassified as severe asthmatics and treated 
with systemic corticosteroids or high-dose ICS prior to their PCD diagnosis. The iPCD cohort 
has data on corticosteroid use for only a few patients, so we could not test this hypothesis. 
Conclusions 
Future research should collect longitudinal data, ideally from birth into adulthood, to evaluate 
changes in height, BMI, and lung function over time, and investigate the direction of their 
association using appropriate statistical approaches [41]. This will also allow assessing the role 
of different treatment strategies and recurrent infections on growth and the course of lung 
function. From a clinical perspective, our findings suggest that early diagnosis followed by 
multidisciplinary management could delay disease progression and improve growth. Monitoring 
height and BMI and, if necessary, early nutritional interventions should become part of routine 
care in PCD clinics to maximise lung growth and delay disease progression. 
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FIGURE LEGENDS 
 
Fig 1. Height in PCD patients by age group A) compared to national references and B) 
compared to WHO references.  
Height is presented as mean z-score (95%CI) after adjusting for sex, country, and level of 
diagnostic certainty. 
 
Fig 2. Height and BMI in PCD patients by country A) compared to national references and B) 
compared to WHO references.  
Height and BMI are presented as mean z-score (95%CI) after adjusting for sex, age group, and 
level of diagnostic certainty. 
Patients from Serbia were included only in the analysis using the WHO references because no 
national growth references were available. 
 
Fig 3. BMI in PCD patients by age group A) compared to national references and B) compared 
to WHO references.  
BMI is presented as mean z-score (95%CI) after adjusting for sex, country, and level of 
diagnostic certainty. 
 
Fig 4. Association of height and BMI with FEV1 and FVC in PCD patients, using national 
references. 
Height and BMI are presented as z-scores after adjusting for sex, country, and level of 
diagnostic certainty. FEV1 and FVC are presented as z-scores calculated using the GLI 
references.  
One measurement (the first available) per patient included. 
Z-score increase per additional FEV1 z-score 1) in height: 0.05, p<0.001, 95% CI 0.04 to 0.07 
and 2) in BMI: 0.17, p<0.001, 95% CI 0.15 to 0.19. 
Z-score increase per additional FVC z-score 1) in height: 0.03, p<0.001, 95% CI 0.02 to 0.05 
and 2) in BMI: 0.17, p<0.001, 95% CI 0.09 to 0.24. 
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Table 1. Characteristics of the study population (N=1609) 
Characteristic n % 
Sex   
Male 780 49 
Female 829 51 
Country of residence*   
Australia 55 3 
Northern Europe 390 24 
Western Europe 405 25 
Eastern Europe 97 6 
Southern Europe 46 3 
Western Asia 202 13 
North America 414 26 
Organ laterality   
Situs solitus 827 51 
Situs inversus 587 37 
Heterotaxia 51 3 
Situs status not reported 144 9 
Date of birth   
Earlier than 1976 252 16 
1977-1996 497 31 
1997-2015 860 53 
Diagnostic information    
Definite PCD diagnosis+ 1,056 66 
Probable PCD diagnosis#  256 16 
Clinical diagnosis only  297 18 
Age at diagnosis 
0-9 years 
10-19 years 
20-29 years 
30-39 years 
40-49 years 
≥50 years 
 
800 
451 
129 
93 
72 
64 
 
50 
28 
8 
6 
4 
4 
* Based on geographical region definitions of the United Nations Statistics Division (August 2016):  
Northern Europe: Denmark, Norway, United Kingdom; Western Europe: Belgium, France, 
Germany, Switzerland, the Netherlands; Eastern Europe: Poland; Southern Europe: Italy, 
Serbia; Western Asia: Cyprus, Israel, Turkey; Northern America: Canada, United States; 
Southern America: Argentina 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation 
identified based on the ERS PCD Diagnostics Task Force guidelines 
# Abnormal light or high frequency video microscopy finding and/or low (≤ 77nl/min) nasal NO 
value 
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Table 2. Height and BMI of PCD patients of the iPCD Cohort compared to national and WHO 
references (constant only models) 
 
 
Reference  N mean  
z-score 
95% CI p-value 
Overall study population National* 1601 -0.27 -0.33 -0.21 <0.001 
Overall study population WHO 1609 -0.12 -0.17 -0.06 <0.001 
Paediatric population (<20 y) National* 1226 -0.26 -0.33 -0.20 <0.001 
Adult population (≥20 y) National* 439 -0.31 -0.42 -0.20 <0.001 
Patients with definite PCD+  National* 1054 -0.26 -0.33 -0.19 <0.001 
 Overall study population¶ National* 1601 -0.30 -0.36 -0.24 <0.001 
Overall study population National* 1549 0.06 0.002 0.13 0.043 
Overall study population WHO 1539 0.21  0.14 0.27 <0.001 
Paediatric population (<20 y) National* 1184 0.02 -0.05 0.09 0.582 
Patients with definite PCD+ National* 1019 0.05 -0.02 0.13 0.172 
 Overall study population¶ National* 1549 0.03 -0.04 0.09 0.424 
* Patients from Serbia were excluded from this analysis because no national references were available 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified based on the ERS 
PCD Diagnostics Task Force guidelines 
¶ Analysis included one measurement (the earliest available) per patient  
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Table 3. Height of PCD patients (N=1601) of the iPCD Cohort compared to 
national height references by characteristics of the study population 
Characteristics  n mean 
z-score 
95% CI p-value¶ 
Sex     0.072 
male  774 -0.22 -0.30 -0.13 
female  827 -0.32 -0.40 -0.24 
Age group*                                                      <0.001 
0-9 y  683 -0.27 -0.33 -0.21 
10-19 y  683 -0.31 -0.37 -0.25 
20-29 y 199 -0.22 -0.29 -0.14 
30-39 y 119 -0.20 -0.29 -0.11 
40-49 y 89 -0.22 -0.32 -0.12 
>50y  79 -0.23 -0.35 -0.11 
Country     <0.001 
Australia 55 -0.31 -0.60 -0.01 
Belgium 79 -0.66 -0.92 -0.40 
Cyprus 30 -0.14 -0.53 0.26 
Denmark 91 -0.36 -0.59 -0.14 
France 119 0.18 -0.03 0.39 
Germany 94 -0.76 -0.99 -0.53 
Israel 142 -0.50 -0.70 -0.31 
Italy 38 -0.41 -0.77 -0.06 
Netherlands 66 -0.18 -0.45 0.09 
Norway 22 -0.64 -1.10 -0.17 
Poland 97 -0.22 -0.46 0.02 
Switzerland 47 -0.01 -0.32 0.29 
Turkey 30 -1.09 -1.51 -0.66 
UK 277 -0.15 -0.29 -0.01 
USA/Canada 414 -0.16 -0.30 -0.05 
Diagnostic certainty            0.897 
Definite PCD diagnosis+ 1,054 -0.28 -0.35 -0.21 
Probable PCD diagnosis#  254 -0.27 -0.42 -0.12 
Clinical diagnosis only  293 -0.24 -0.37 -0.10 
Mean z-scores and 95%CI for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating if the characteristic explains differences in height within 
the study population;  
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified 
based on the ERS PCD Diagnostics Task Force guidelines 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value 
* Age at measurement: n represents the unique number of patients in each group 
Patients from Serbia were excluded from this analysis because no national references were 
available 
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Table 4. BMI of paediatric patients (<20 years, N=1184) of the iPCD Cohort compared  
to national BMI references by characteristics of the study population 
Characteristics n mean 
z-score 
95% CI p-value¶ 
Sex     0.605 
male 610 0.04 -0.06 0.13 
female 574 -0.0002 -0.10 0.10 
Age group*                                                      <0.001 
0-4 y 226 -0.24 -0.35 -0.13 
5-9 y 504 -0.01 -0.09 0.07 
10-14 y 475 0.05 -0.03 0.13 
15-19 y 322 0.22 0.13 0.31 
Country     0.004 
Australia 44 -0.07 -0.42 0.28 
Belgium 38 -0.33 -0.73 0.07 
Cyprus 17 -0.44 -0.98 0.10 
Denmark 74 -0.01 -0.27 0.25 
France 118 0.09 -0.13 0.31 
Germany 82 -0.22 -0.48 0.05 
Israel 100 -0.05 -0.30 0.20 
Italy 33 0.41 0.02 0.80 
Netherlands 50 0.23 -0.10 0.56 
Norway 19 -0.62 -1.14 -0.10 
Poland 82 0.02 -0.26 0.30 
Switzerland 32 -0.10 -0.49 0.29 
Turkey 30 -0.51 -0.97 -0.05 
UK 182 0.03 -0.15 0.21 
USA/Canada 283 0.21 0.05 0.36 
Diagnostic certainty            0.829 
Definite PCD diagnosis+ 767 0.004 -0.08 0.09 
Probable PCD diagnosis#  197 0.03 -0.16 0.21 
Clinical diagnosis only 220 0.07 -0.11 0.24 
Age at diagnosis     <0.001 
0-4 y 351 0.24 0.11 0.38 
5-9 y 413 0.04 -0.08 0.16 
10-14 y 272 -0.07 -0.22 0.08 
15-19 y 141 -0.43 -0.64 -0.22 
Mean z-scores (95%CI) for each group after adjusting for the remaining characteristics 
¶ Likelihood ratio test p-value indicating if the characteristic explains differences in BMI within the 
study population 
+ Defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation identified 
based on the ERS PCD Diagnostics Task Force guidelines 
# Abnormal light or high frequency video microscopy finding and/or low nasal NO value 
* Age at measurement: n represents the unique number of patients in each group 
Patients from Serbia were excluded from this analysis because no national references were available 
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